FIRST EVIDENCE OF PROGESTERONE METABOLITES (4-PREGNENE) EFFECTS IN HUMAN OVARIAN CANCER CELL LINES.

PELEGRINA LT; SANHUEZA MA; CÁCERES ARR; IBAÑEZ CANNAVÓ J; CARDONE DA; LACONI MR

Simposio; INTERNATIONAL SYMPOSIUM ON REPRODUCTIVE HEALTH; 2021

ISRH - Buenos Aires, Argentina

Ovarian cancer is the fifth leading cause of cancer-related death among women and is the second most common type of gynecologic cancer diagnosed during pregnancy. It is known that ovarian cancer is detected in advanced stages of the disease. Although the incidence of ovarian cancer in pregnancy is low and the maternal-fetal prognosis is generally favorable for the early stages of the tumor, management depends on the stage of the disease, the length of gestation, and the patient's wishes. Termination of pregnancy in the early stages is usually the main decision of patients who prioritize treatment or the desire to preserve reproductive capacity. Among the most important hormones for the maintenance of pregnancy, progesterone and its metabolites present a sustained increase until the time of delivery. Currently, the role of progesterone in ovarian carcinogenesis is controversial. This hormone can be metabolized into the 4-pregnenes, 3α-di-hydroprogesterone and 20α-dihydroprogesterone derivatives. These steroids are active and have anti-tumor effects in breast cancer. Here, we evaluated the effect of 4-pregenenes derivates on cell proliferation (MTT), and tumor migration (wound assay) of two human ovarian cancer lines, IGROV-1 and SKOV-3. In both lines, 3α-di-hydroprogesterone and 20α-dihydro-progesterone significantly reduced proliferation of the ovarian cancer cell lines. Migration, a critical event in metastasis formation, was significantly stimulated by 20α-dihydro-progesterone on IGROV-1. This effect was concentration-dependent with a maximum of 298% for 10-11M (p